Clinical Trials for Pancreas Cancer

A Phase 2 Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas Adenocarcinoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Metastatic, treatment-naïve PDAC (ECOG 0–1) receiving first-line gemcitabine/nab-paclitaxel plus motixafortide (CXCR4 antagonist to disrupt stroma and enhance immune infiltration) and cemiplimab (PD‑1 inhibitor); requires measurable disease and biopsy-accessible tumor. Excludes prior PDAC therapy, active autoimmune disease requiring treatment, CNS mets, uncontrolled infections/hepatitis/HIV, and significant comorbidity.

ClinicalTrials.gov ID: NCT04543071

A Phase I/Ib Trial of ProAgio, an Anti- αvβ3 Integrin Cytotoxin, in Combination With Gemcitabine and Nab-paclitaxel for Advanced Pancreatic Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Previously untreated adults with metastatic PDAC (ECOG 0–1) receive ProAgio—an investigational pegylated peptide that targets integrin αvβ3 on cancer‑associated fibroblasts and endothelial cells to induce apoptosis and remodel stroma/vasculature—alone and in combination with standard gemcitabine plus nab‑paclitaxel. Excludes prior gem/nab‑paclitaxel and significant neuropathy, unstable autoimmune/cardiovascular disease, serious infection, or untreated/unstable CNS metastases.

ClinicalTrials.gov ID: NCT06182072

Multi-agent Low Dose Chemotherapy (Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, Irinotecan) Followed by Maintenance Olaparib and Pembrolizumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously untreated metastatic PDAC (ECOG 0–1) receive low-dose multi-agent induction chemotherapy (gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan), then transition to maintenance pembrolizumab (anti–PD-1) plus olaparib (PARP inhibitor) with biopsy required and no prior PD-1/PD-L1 or PARP exposure. Designed to test whether PARP inhibition combined with PD-1 blockade can maintain disease control beyond biomarker-restricted subsets following cytotoxic induction.

ClinicalTrials.gov ID: NCT04753879

Phase I/II Study of Anti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells (EGFR FPBMC) in Metastatic or Unresectable Pancreatic Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/locally advanced or metastatic pancreatic adenocarcinoma after at least one prior systemic regimen (and prior targeted/immunotherapy when indicated), ECOG 0–1, receive repeated infusions of autologous PBMCs armed ex vivo with an anti-CD3 × anti-EGFR bispecific antibody that redirects T-cell cytotoxicity to EGFR-expressing tumors. Treatment involves 8 weekly infusions followed by 8 biweekly infusions after a second leukapheresis; key exclusions include EGFR mAb hypersensitivity, active infections, and autoimmune disease requiring immunosuppression.

ClinicalTrials.gov ID: NCT06479239

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 (Spevatamig) Followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/metastatic CLDN18.2-positive gastric/GEJ, pancreatic ductal, or biliary tract adenocarcinomas receive spevatamig (PT886)—a bispecific antibody targeting CLDN18.2 and CD47 to enhance macrophage-mediated phagocytosis—given as monotherapy or combined with chemotherapy (e.g., paclitaxel, gemcitabine/nab-paclitaxel, FOLFOX, CAPOX, FOLFIRINOX) and/or pembrolizumab. Cohorts are line- and disease-specific, with CLDN18.2 expression ≥10% at ≥2+ required for combination parts.

ClinicalTrials.gov ID: NCT05482893

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with CLDN18.2-positive advanced/metastatic gastric, GEJ, esophageal, or pancreatic adenocarcinoma after prior systemic therapy receive AZD5863 monotherapy, a CLDN18.2×CD3 T cell–engaging bispecific antibody, via IV or SC administration. Trial focuses on dose finding and preliminary efficacy with RECIST-measurable disease and ECOG 0–1 required.

ClinicalTrials.gov ID: NCT06005493

A Phase I Study of Autologous CAR-T Cells Targeting the B7-H3 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Refractory Pancreatic Ductal Adenocarcinoma (PDAC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory/relapsed pancreatic ductal adenocarcinoma (ECOG 0–1) receive a single infusion of autologous B7-H3 (CD276)–targeted CAR-T cells incorporating an inducible caspase-9 safety switch. Dose-escalation evaluates safety/tolerability and feasibility; bridging therapy may be used pre-infusion.

ClinicalTrials.gov ID: NCT06158139

A Phase I/Ib Pilot Trial, Single Arm, Open Label, of Protein-Bound Paclitaxel, Cisplatin, and Gemcitabine (GCN) Combined With Tumor Treatment Fields (TTF) in Patient With Metastatic Pancreatic Adenocarcinoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with untreated metastatic pancreatic adenocarcinoma (including adenosquamous) with liver metastasis, ECOG 0–1, and no brain mets receive modified gemcitabine/cisplatin/nab-paclitaxel every 2 weeks plus continuous Tumor Treating Fields (TTF), followed by maintenance gemcitabine with TTF. TTF is a noninvasive device therapy delivering alternating electric fields that disrupt mitosis; key exclusions include significant cardiac conduction issues/implantable stimulators and inability to use the device.

ClinicalTrials.gov ID: NCT04605913

A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced/metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) receive the anti-PAUF monoclonal antibody PBP1510 (ulenistamab)—a first-in-class IgG1 that neutralizes PAUF-mediated ERK/JNK/AKT and TLR2/4 signaling—given as monotherapy in dose escalation and then combined with gemcitabine at RP2D. Prior gemcitabine is allowed (unless stopped for intolerance), and the expansion focuses on PBP1510 plus gemcitabine to assess safety and antitumor activity.

ClinicalTrials.gov ID: NCT05141149

Phase I Trial of MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Untreated metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) receiving mFOLFIRINOX plus oral zunsemetinib, an investigational inhibitor of the p38α–MK2 signaling axis intended to reduce proinflammatory cytokine expression and potentially chemosensitize tumors. Key exclusions include CNS metastases, ≥grade 2 neuropathy, significant ILD, QTcF >460 ms, strong CYP3A4/2C8 modulators, and QT‑prolonging drugs.

ClinicalTrials.gov ID: NCT06648434